Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

PRODUCT THEATERS, INDUSTRY THEATERS, COMPANY SHOWCASES

December 11, 2021

(Listing updated November 10, 2021) 

Product Theaters 

Saturday, December 11 
11:30 a.m.-12:30 p.m. 


Theater 1
In-Person Participants Only 
A Treatment Option for Adults With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) After At Least Two Prior Lines of Systemic Therapy*

Sponsored by: Bristol Myers Squibb 
Speaker: 
Mecide Gharibo, MD, Vice President, U.S. Medial Affairs Hematology, Bristol Myers Squibb 


Theater 2 
In-Person Participants Only
IMBRUVICA® (ibrutinib) Long Term Efficacy and Safety Clinical Trial Data

Sponsored by: Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
Speaker: James Dean, MD, PhD, Global Development Lead, Imbruvica Oncology Development, Pharmacyclics LLC, an AbbVie Company 

Theater 3 
In-Person Participants Only 
AYVAKIT: Now approved for advanced systemic mastocytosis*
Sponsored by: Blueprint Medicines 
Speaker: Robyn M. Scherber, MD, MPH, Senior Medical Director, Blueprint Medicines
 

Theater 4 
Evolving CLL Treatment Paradigm
 
Sponsored by: AbbVie 
Speaker: 
R. Frank Cornell, MD, MS, Medical Director, U.S. Medical Affairs, AbbVie 

Theater 5 
Study Design for Anemia of MDS and Chemotherapy Induced Anemia 
Sponsored by: AstraZeneca 
Speaker: 
Katharina Modelska, MD, PhD, FibroGen 

Theater 6 
In-Person Participants Only
 
BLENREP (belantamab mafodotin-blmf) for Injection 100mg (Includes 6-Month Clinical Data and Updated Data From 13-Month Follow-Up)*
Sponsored by: GSK 
Speaker: 
Ira Gupta, MD, Vice President, Medicine Development Leader, GSK 
*Presentation is intended for U.S.-based registered meeting attendees 

 

Sunday, December 12 
8:00-9:00 a.m. 


Theater 1
A Treatment Option for Patients with Myelodysplastic Syndromes
 
Sponsored by: Bristol Myers Squibb
 Speaker: Christina Hughes, PhD, Director, WW Medical Affairs, Hematology Myeloid, Bristol Myers Squibb 

Theater 2 
Rare Bleeding Disorders in Girls and Women: The Use of a rFVIIa Product
Sponsored by: Novo Nordisk 
Speakers: Stephanie Seremetis, MD, CVP and Chief Medical Officer, Bio- pharm, Novo Nordisk 

Theater 3
In-Person Participants Only
 
An Effective Oral TPO-RA: DOPTELET® (avatrombopag) for Adult Patients With Chronic Immune Thrombocytopenia (ITP)

Sponsored by: Sobi 
Speaker: 
Scott Kolodny, MD, Senior Director, North American Medical Affairs, Sobi 

 

Sunday, December 12 
11:30 a.m.-12:30 p.m. 


Theater 1
In-Person Participants Only 
Pivotal Phase 3 Data in Newly Diagnosed AML: Exploring the Efficacy, Safety, and Patient Management of Evolving AML Treatment Paradigms*
Sponsored by: Genentech 
Speaker: 
Grace Ku, MD, Global Development Leader- Venetoclax Myeloid, Multiple Myeloma, Pediatrics, Genentech 


Theater 2
The Time Is Now: Evidence for Actionability of clonoSEQ MRD Assessment in Lymphoid Cancer Patient Care* 
Sponsored by: Adaptive Biotechnologies
 
Speaker: 
Allison Jacob, Medical Director, clonoSEQ, Adaptive Biotechnologies 


Theater 3 
In-Person Participants Only

Evolving Treatment Approaches in MDS & CMML 
Sponsored by: Taiho Oncology
 
Speaker: 
Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology/Astex Pharmaceuticals 

Theater 4 
The Increasing Reach of CAR T-cell therapy: The Kite Story 
Sponsored by: Kite, a Gilead Company  
Speakers: 
Warner Biddle, Senior Vice President, Global Head of Commercial, Kite, a Gilead Company; Frank Neumann, Senior Vice President, Global Head of Clinical Development, Kite, a Gilead Company; Charles Calderaro, Senior Vice President, Global Head of Technical Operations, Kite, a Gilead Company 


Theater 5
 

Haematology R&D at AstraZeneca; Novel Strategies, Targets, and Treatment for Blood 
Sponsored by: AstraZeneca 
Speakers: 
Raoul Tibes, MD, Global Head Leukemia Strategy & Clinical Development, AstraZeneca; Robert Chen, MD, Global Head of Lymphoma Clinical Development and Strategy, AstraZeneca; Simon Rule, MD, Global Head of Calquence, AstraZeneca 

Theater 6 
In-Person Participants Only
 
A Treatment Option for Adult Patients With Newly Diagnosed CP Ph+ CML or Patients With CML Resistant/Intolerant to Prior TKI Therapy

Sponsored by: Pfizer Inc.
 
Speaker: 
Erinn Hoag Goldman, PhD, Medical Director, Hematology, U.S. Medical Affairs, Pfizer Inc.
 

Virtual Meeting Platform Only  
Importance of Sustained Terminal Complement Inhibition in PNH

Sponsored by: Alexion Pharmaceuticals Inc.
 
Speaker: 
Anita Hill, MD, PhD, Global Medical Affairs Lead Haematology & Nephrology and Consultant for Clinical Development, Alexion Pharmaceuticals Inc. 
*Presentation is intended for U.S.-based registered meeting attendees 

 


Monday, December 13 
8:00-9:00 a.m. 


Theater 1 
A Treatment Option for Patients with Acute Myeloid Leukemia 
Sponsored by: Bristol Myers Squibb 
Speaker: 
Ali McBride, Director Hematology HEOR, Bristol Myers Squibb 

 


Monday, December 13
12:15-1:15 p.m. 


Theater 1

ZYNLONTA® (loncastuximab tesirinelpyl), the First-and-Only CD19-Targeted ADC, for the Treatment 
of Adults with R/R DLBCL After Two or More Lines of Systemic Therapy 
Sponsored by: ADC Therapeutics 
 
Speaker: 
Joseph Camardo, MD, Chief Medical Officer, ADC Therapeutics 

Theater 2 
In-Person Participants Only 
Case Study: A 19-Year-Old Female With Distal Radius Fracture and Anemia
 
Sponsored by: Agios
 
Speakers
: Amber Yates, MD, FAAP, Medical Director, Agios; Felix Chapovsky, MD, Medical Director, Agios 

Theater 3 
In-Person Participants Only
 
Cytopenic Myelofibrosis and an Introduction to Pacritinib* 

Sponsored by: CTI BioPharma Corp.
 
Speaker: 
Sarah Buckley, MD, Senior Medical Director, CTI BioPharma Corp. 

Theater 4 
In-Person Participants Only 
 
Discussion in the Treatment of Sickle Cell Disease, Moving Beyond Pain As a Primary Target 

Sponsored by: Global Blood Therapeutics
 
Speaker: 
Kim Smith-Whitley, MD, Executive Vice President, Head of Research and Development, Global Blood Therapeutics 

Theater 5 
In Adult and Pediatric Patients 12 Years and Older with Chronic GVHD, Intervene with Jakafi® (ruxolitinib) At the First Sign of Initial Systemic Treatment Failure 
 
Sponsored by: Incyte 
Speaker: John P Galvin MD, MPH, MS, Senior Medical Director, Graft versus Host Disease, Incyte, Assistant Professor, University of Illinois Chicago 

Theater 6 
In-Person Participants Only  
Redefining Frontline Therapy in Transplant Ineligible Multiple Myeloma Patients: MAIA 5-year Update including Overall Survival 
Sponsored by: Janssen Biotech  
Speaker: Thomas Lin, MD, PhD, Head of Multiple Myeloma, U.S. Medical Affairs, Janssen Oncology 

Theater 7 
A Breakthrough in aTTP Treatment  
Sponsored by: Sanofi Genzyme  
Speaker: Rui De Passos Sousa, MD, Global Medical Head - TTP, ITP and Pemphigus, Sanofi Genzyme 

*This presentation is intended for U.S.-based registered meeting attendees 

Industry Theaters 

Saturday, December 11 
11:30 a.m.-12:30 p.m. 

Theater 7 
Pfizer’s Leadership Through Science: Driving Innovation in Hematology* 
Sponsored by: Pfizer Inc. 
Speakers: Andy Schmeltz, Global President & General Manager, Pfizer Oncology; Dany Habr, MD, Chief Medical Officer, Pfizer Oncology; Vali Papadimitrakopoulou, MD, Vice President, Head of Clinical Development, Global Product Development, Pfizer Oncology 

 

Sunday, December 12 
11:30 a.m.-12:30 p.m. 

Theater 7 
Immune System Unleashed: Leveraging the Innate Immune System in HR-MDS 
Sponsored by: Gilead Sciences  
Speaker: Carol O’Hear, MD, PhD, Vice President, Oncology Clinical Development, Gilead Sciences 

 

Company Showcases 

Saturday, December 11 
1:30-1:45 p.m. 


Theater 5 
In-Person Participants Only  
Emerging Standard Single Cell Functional Biomarkers of Immune Function and Potency, and Duomic, a Novel Simultaneous Single Cell Transcriptomics and Functional Proteomics Platform to Transform Connected Therapeutic Biology  
Sponsored by: IsoPlexis 
Speaker: Chase Migliore, Proteomics Specialist, IsoPlexis 

Theater 6 
Genetic Therapy in Hemoglobinopathies 
Sponsored by: Vertex Pharmaceuticals 
Speaker: William Hobbs, MD, PhD, Vice President, Clinical Development, Hematology, Vertex Pharmaceuticals 

Theater 7 
In-Person Participants Only 
Duplex Sequencing for Ultra-Low Frequency Measurable Residual Disease Detection 
Sponsored by: TwinStrand Biosciences Speakers: Jesse Salk, MD, PhD, Chief Executive Officer, TwinStrand Biosciences; Jake Higgins, PhD, Senior Scientist, TwinStrand Biosciences 

Virtual Meeting Platform Only 
UCB Showcase of Commitment to Patients With ITP 
Sponsored by: UCB Biopharma 
Speaker: Donatello Crocetta, MD, MBA, Head of Medical Affairs, Rare Diseases, UCB Biopharma 

 


Sunday, December 12 
4:00-4:15 p.m. 

Theater 7 
In-Person Participants Only  
Introduction to Alnylam Pharmaceutical and a Treatment Option for Adults with Acute Hepatic Porphyria Featuring 24-month data from the ENVISION Open-Label Extension (OLE) Study 
Sponsored by: Alnylam Pharmaceuticals 
Speaker: Laurent Placidi, PharmD, PhD, Program Lead, Acute Hepatic Porphyria, Alnylam Pharmaceuticals 

 

Monday, December 13 
10:00-10:15 a.m. 


Theater 7 
Unleashing the Power of Single-Cell Multimodal Analysis to Advance Precision Medicine 
Sponsored by: Mission Bio 
Speaker: Aaron Llanso, Director of Translational Application and Market Development, Mission Bio 

Virtual Meeting Platform Only 
The Syros Clinical Stage Pipeline in Targeted Hematology Therapies. Overview of Novel Small Molecule Gene Control Medicines in Development for MDS, AML, APL and NHL  
Sponsored by: Syros 
Speaker: David Roth, MD, Chief Medical Officer, Syros 

Close Modal

or Create an Account

Close Modal
Close Modal